nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.07.2013 | Neuro-Oncology (LE Abrey, Section Editor)

Health-related Quality of Life in Patients with Brain Tumors: Limitations and Additional Outcome Measures

verfasst von: Linda Dirven, Jacob C. Reijneveld, Neil K. Aaronson, Andrew Bottomley, Bernard M. J. Uitdehaag, Martin J. B. Taphoorn

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Health-related quality of life (HRQOL) is a multidimensional concept used to measure patients’ functioning and well-being. In recent decades, HRQOL has become an important (secondary) outcome measure in clinical trials for brain tumor patients. It could be questioned, however, whether HRQOL is the only useful outcome measure for assessing the level of functioning and well-being of these patients. As described in this review, several general methodological issues can hamper the interpretation of HRQOL data collected in the oncology setting. Additionally, because brain tumor patients have a progressive brain disease resulting in cognitive impairments, patient-reported outcomes may not always be the most informative and accurate measures of HRQOL in brain tumor patients. Supplementary or alternative measures, such as proxy-rated HRQOL measures and measures of instrumental activities of daily living, may provide a more complete picture of brain tumor patients’ functioning in daily life.

Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.PubMedCrossRef

Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet. 2003;361:323–31.PubMedCrossRef

Ranjan T, Abrey LE. Current management of metastatic brain disease. Neurotherapeutics. 2009;6:598–603.PubMedCrossRef

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.PubMedCrossRef

Efficace F, Taphoorn M. Methodological issues in designing and reporting health-related quality of life in cancer clinical trials: the challenge of brain cancer studies. J Neurooncol. 2012;108:221–6.PubMedCrossRef

Efficace F, Bottomley A. Health related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer patients. Eur J Cancer. 2002;38:1824–31.PubMedCrossRef

Aaronson NK. Quality of life: what is it? How should it be measured? Oncology (Williston Park). 1988;2:69–76.PubMed

Aaronson NK, Taphoorn MJ, Heimans JJ, Postma TJ, Gundy CM, Beute GN, et al. Compromised health-related quality of life in patients with low-grade glioma. J Clin Oncol. 2011;29:4430–5.PubMedCrossRef

Caissie A, Nguyen J, Chen E, Zhang L, Sahgal A, Clemons M, et al. Quality of life in patients with brain metastases using the EORTC QLQ-BN20+2 and QLQ-C15-PAL. Int J Radiat Oncol Biol Phys. 2012;83:1238–45.PubMedCrossRef

10.

Gronberg BH, Ciuleanu T, Flotten O, Knuuttila A, Abel E, Langer SW, et al. A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer. Lung Cancer. 2012;78:63–9.PubMedCrossRef

11.

Ma S, Xu Y, Deng Q, Yu X. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer. 2009;65:198–203.PubMedCrossRef

12.

Steinmann D, Paelecke-Habermann Y, Geinitz H, Aschoff R, Bayerl A, Bolling T, et al. Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases. BMC Cancer. 2012;12:283.PubMedCrossRef

13.

Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48:2192–202.PubMedCrossRef

14.

Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:937–44.PubMedCrossRef

15.

Taphoorn MJ, van den Bent MJ, Mauer ME, Coens C, Delattre JY, Brandes AA, et al. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol. 2007;25:5723–30.PubMedCrossRef

16.

Yaneva MP, Semerdjieva MA. Assessment of the effect of palliative radiotherapy for cancer patients with intracranial metastases using EORTC-QOL-C30 questionnaire. Folia Med (Plovdiv). 2006;48:23–9.PubMed

17.

Yavas C, Zorlu F, Ozyigit G, Gurkaynak M, Yavas G, Yuce D, et al. Health-related quality of life in high-grade glioma patients: a prospective single-center study. Support Care Cancer. 2012;20:2315–25.PubMedCrossRef

18.

Kirkbride P, Tannock IF. Trials in palliative treatment–have the goal posts been moved? Lancet Oncol. 2008;9:186–7.PubMedCrossRef

19.

Arpinelli F, Bamfi F. The FDA guidance for industry on PROs: the point of view of a pharmaceutical company. Health Qual Life Outcomes. 2006;4:85.PubMedCrossRef

20.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.PubMedCrossRef

21.

Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res. 1996;5:139–50.PubMedCrossRef

22.

Taphoorn MJ, Claassens L, Aaronson NK, Coens C, Mauer M, Osoba D, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer. 2012;46:1033–40.CrossRef

23.

Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer. 1995;75:1151–61.PubMedCrossRef

24.

Armstrong TS, Mendoza T, Gning I, Coco C, Cohen MZ, Eriksen L, et al. Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J Neurooncol. 2006;80:27–35.PubMedCrossRef

25.

Armstrong TS, Gning I, Mendoza TR, Weinberg JS, Gilbert MR, Tortorice ML, et al. Clinical utility of the MDASI-BT in patients with brain metastases. J Pain Symptom Manage. 2009;37:331–40.PubMedCrossRef

26.

Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA. 2002;288:3027–34.PubMedCrossRef

27.

Hilarius DL, Kloeg PH, Gundy CM, Aaronson NK. Use of health-related quality-of-life assessments in daily clinical oncology nursing practice: a community hospital-based intervention study. Cancer. 2008;113:628–37.PubMedCrossRef

28.

Taphoorn MJ, Sizoo EM, Bottomley A. Review on quality of life issues in patients with primary brain tumors. Oncologist. 2010;15:618–26.PubMedCrossRef

29.

Cheng JX, Zhang X, Liu BL. Health-related quality of life in patients with high-grade glioma. Neuro Oncol. 2009;11:41–50.PubMedCrossRef

30.

Vordermark D. Avoiding bias in the prospective evaluation of patients with brain metastases. J Clin Oncol. 2007;25:4023–5.PubMedCrossRef

31.

Gallego Perez-Larraya J, Ducray F, Chinot O, Catry-Thomas I, Taillandier L, Guillamo JS, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol. 2011;29:3050–5.PubMedCrossRef

32.

Levin VA, Phuphanich S, Yung WK, Forsyth PA, Maestro RD, Perry JR, et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol. 2006;78:295–302.PubMedCrossRef

33.

Mauer ME, Bottomley A, Taphoorn MJ. Evaluating health-related quality of life and symptom burden in brain tumour patients: instruments for use in experimental trials and clinical practice. Curr Opin Neurol. 2008;21:745–53.PubMedCrossRef

34.

Reijneveld JC, Klein M, Taphoorn MJ, Postma TJ, Heimans JJ. Improved, personalized treatment of glioma necessitates long-term follow-up of cognitive functioning. Pharmacogenomics. 2012;13:1667–9.PubMedCrossRef

35.

Osoba D. What has been learned from measuring health-related quality of life in clinical oncology. Eur J Cancer. 1999;35:1565–70.PubMedCrossRef

36.

Hakamies-Blomqvist L, Luoma ML, Sjostrom J, Pluzanska A, Sjodin M, Mouridsen H, et al. Timing of quality of life (QoL) assessments as a source of error in oncological trials. J Adv Nurs. 2001;35:709–16.PubMedCrossRef

37.

Klee MC, King MT, Machin D, Hansen HH. A clinical model for quality of life assessment in cancer patients receiving chemotherapy. Ann Oncol. 2000;11:23–30.PubMedCrossRef

38.

Pater J, Osoba D, Zee B, Lofters W, Gore M, Dempsey E, et al. Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial. Qual Life Res. 1998;7:273–8.PubMedCrossRef

39.

Ediebah DE, Coens C, Maringwa JT, Quinten C, Zikos E, Ringash J, et al. Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients. Ann Oncol. 2013;24:231–7.PubMedCrossRef

40.

Osoba D. Rationale for the timing of health-related quality-of-life (HQL) assessments in oncological palliative therapy. Cancer Treat Rev. 1996;22(A):69–73.PubMedCrossRef

41.

Fairclough DL, Cella DF. Functional Assessment of Cancer Therapy (FACT-G): non-response to individual questions. Qual Life Res. 1996;5:321–9.PubMedCrossRef

42.

Walker M, Brown J, Brown K, Gregor A, Whittle IR, Grant R. Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma. J Neurooncol. 2003;63:179–86.PubMedCrossRef

43.

Rubin DB. Inference and missing data. Biometrika. 1976;63:581–92.CrossRef

44.

Little R, Rubin D. Statistical Analysis with Missing Data. New York: Wiley; 1987.

45.

Post WJ, Buijs C, Stolk RP, de Vries EG, le Cessie S. The analysis of longitudinal quality of life measures with informative drop-out: a pattern mixture approach. Qual Life Res. 2010;19:137–48.PubMedCrossRef

46.

Walther B, Hossin S, Townend J, Abernethy N, Parker D, Jeffries D. Comparison of electronic data capture (EDC) with the standard data capture method for clinical trial data. PLoS One. 2011;6:e25348.PubMedCrossRef

47.

Maringwa J, Quinten C, King M, Ringash J, Osoba D, Coens C, et al. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Ann Oncol. 2011;22:2107–12.PubMedCrossRef

48.

Kvam AK, Wisloff F, Fayers PM. Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma. Health Qual Life Outcomes. 2010;8:79.PubMedCrossRef

49.

Schwartz CE, Bode R, Repucci N, Becker J, Sprangers MA, Fayers PM. The clinical significance of adaptation to changing health: a meta-analysis of response shift. Qual Life Res. 2006;15:1533–50.PubMedCrossRef

50.

Schwartz CE, Sprangers MA. Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Soc Sci Med. 1999;48:1531–48.PubMedCrossRef

51.

Sprangers MA, Schwartz CE. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med. 1999;48:1507–15.PubMedCrossRef

52.

Rapkin BD, Schwartz CE. Toward a theoretical model of quality-of-life appraisal: Implications of findings from studies of response shift. Health Qual Life Outcomes. 2004;2:14.PubMedCrossRef

53.

Barclay-Goddard R, Epstein JD, Mayo NE. Response shift: a brief overview and proposed research priorities. Qual Life Res. 2009;18:335–46.PubMedCrossRef

54.

Hamidou Z, Dabakuyo TS, Bonnetain F. Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trials. Expert Rev Pharmacoecon Outcomes Res. 2011;11:549–59.PubMedCrossRef

55.

Ubel PA, Peeters Y, Smith D. Abandoning the language of "response shift": a plea for conceptual clarity in distinguishing scale recalibration from true changes in quality of life. Qual Life Res. 2010;19:465–71.PubMedCrossRef

56.

Nolte S, Elsworth GR, Sinclair AJ, Osborne RH. The inclusion of 'then-test' questions in post-test questionnaires alters post-test responses: a randomized study of bias in health program evaluation. Qual Life Res. 2012;21:487–94.PubMedCrossRef

57.

Schwartz CE, Sprangers MA. Guidelines for improving the stringency of response shift research using the thentest. Qual Life Res. 2010;19:455–64.PubMedCrossRef

58.

McPhail S, Haines T. Response shift, recall bias and their effect on measuring change in health-related quality of life amongst older hospital patients. Health Qual Life Outcomes. 2010;8:65.PubMedCrossRef

59.

Groenvold M, Petersen M. The role and use of differential item functioning (DIF) analysis of quality of life data in clinical trials. In: Fayers P, Hays R, editors. Assessing Quality of Life in Clinical Trials. 2nd ed. Oxford: Oxford University Press; 2008. p. 195–208.

60.

Scott NW, Fayers PM, Bottomley A, Aaronson NK, de Graeff A, Groenvold M, et al. Comparing translations of the EORTC QLQ-C30 using differential item functioning analyses. Qual Life Res. 2006;15:1103–15.PubMedCrossRef

61.

Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, et al. The relationship between overall quality of life and its subdimensions was influenced by culture: analysis of an international database. J Clin Epidemiol. 2008;61:788–95.PubMedCrossRef

62.

King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res. 1996;5:555–67.PubMedCrossRef

63.

Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–44.PubMed

64.

Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, et al. The practical impact of differential item functioning analyses in a health-related quality of life instrument. Qual Life Res. 2009;18:1125–30.PubMedCrossRef

65.

Oberndorfer S, Lindeck-Pozza E, Lahrmann H, Struhal W, Hitzenberger P, Grisold W. The end-of-life hospital setting in patients with glioblastoma. J Palliat Med. 2008;11:26–30.PubMedCrossRef

66.

Pace A, Di LC, Guariglia L, Jandolo B, Carapella CM, Pompili A. End of life issues in brain tumor patients. J Neurooncol. 2009;91:39–43.PubMedCrossRef

67.

Sizoo EM, Braam L, Postma TJ, Pasman HR, Heimans JJ, Klein M, et al. Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neuro Oncol. 2010;12:1162–6.PubMedCrossRef

68.

Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004;3:159–68.PubMedCrossRef

69.

Fayers P, Machin D. Quality of life. Assessment, analysis and interpretation. Chichester: Wiley; 2000.

70.

Sneeuw KC, Sprangers MA, Aaronson NK. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease. J Clin Epidemiol. 2002;55:1130–43.PubMedCrossRef

71.

Brown PD, Decker PA, Rummans TA, Clark MM, Frost MH, Ballman KV, et al. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: comparison of patient and caregiver ratings of quality of life. Am J Clin Oncol. 2008;31:163–8.PubMedCrossRef

72.

Sneeuw KC, Aaronson NK, Osoba D, Muller MJ, Hsu MA, Yung WK, et al. The use of significant others as proxy raters of the quality of life of patients with brain cancer. Med Care. 1997;35:490–506.PubMedCrossRef

73.

Sneeuw KC, Aaronson NK, Sprangers MA, Detmar SB, Wever LD, Schornagel JH. Comparison of patient and proxy EORTC QLQ-C30 ratings in assessing the quality of life of cancer patients. J Clin Epidemiol. 1998;51:617–31.PubMedCrossRef

74.

Stephens RJ, Hopwood P, Girling DJ, Machin D. Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res. 1997;6:225–36.PubMedCrossRef

75.

Moinpour CM, Lyons B, Schmidt SP, Chansky K, Patchell RA. Substituting proxy ratings for patient ratings in cancer clinical trials: an analysis based on a Southwest Oncology Group trial in patients with brain metastases. Qual Life Res. 2000;9:219–31.PubMedCrossRef

76.

• Quinten C, Maringwa J, Gotay CC, Martinelli F, Coens C, Reeve BB, et al. Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst. 2011;103:1851–8. This study examined the extent to which HRQOL scores of cancer patients and clinicians corresponded and if both contributed to the estimation of overall survival. Patient- and clinician-reported HRQOL scores did differ, but contributed independently and positively to survival prognostication. The subjective measure of a patient thus complements clinician scoring in predicting overall survival.PubMedCrossRef

77.

Wilson KA, Dowling AJ, Abdolell M, Tannock IF. Perception of quality of life by patients, partners and treating physicians. Qual Life Res. 2000;9:1041–52.PubMedCrossRef

78.

Milne DJ, Mulder LL, Beelen HC, Schofield P, Kempen GI, Aranda S. Patients' self-report and family caregivers' perception of quality of life in patients with advanced cancer: how do they compare? Eur J Cancer Care (Engl). 2006;15:125–32.CrossRef

79.

Giesinger JM, Golser M, Erharter A, Kemmler G, Schauer-Maurer G, Stockhammer G, et al. Do neurooncological patients and their significant others agree on quality of life ratings? Health Qual Life Outcomes. 2009;7:87.PubMedCrossRef

80.

McPhail S, Beller E, Haines T. Two perspectives of proxy reporting of health-related quality of life using the Euroqol-5D, an investigation of agreement. Med Care. 2008;46:1140–8.PubMedCrossRef

81.

Sprangers MA, Aaronson NK. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review. J Clin Epidemiol. 1992;45:743–60.PubMedCrossRef

82.

Pickard AS, Knight SJ. Proxy evaluation of health-related quality of life: a conceptual framework for understanding multiple proxy perspectives. Med Care. 2005;43:493–9.PubMedCrossRef

83.

Gundy CM, Aaronson NK. The influence of proxy perspective on patient-proxy agreement in the evaluation of health-related quality of life: an empirical study. Med Care. 2008;46:209–16.PubMedCrossRef

84.

Ruge MI, Ilmberger J, Tonn JC, Kreth FW. Health-related quality of life and cognitive functioning in adult patients with supratentorial WHO grade II glioma: status prior to therapy. J Neurooncol. 2011;103:129–36.PubMedCrossRef

85.

Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–86.PubMedCrossRef

86.

Sikkes SA, de Lange-de Klerk ES, Pijnenburg YA, Gillissen F, Romkes R, Knol DL, et al. A new informant-based questionnaire for instrumental activities of daily living in dementia. Alzheimers Dement. 2012;8:536–43.PubMedCrossRef

87.

Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer. 2005;41:280–7.PubMedCrossRef

88.

Bottomley A, Efficace F, Thomas R, Vanvoorden V, Ahmedzai SH. Health-related quality of life in non-small-cell lung cancer: methodologic issues in randomized controlled trials. J Clin Oncol. 2003;21:2982–92.PubMedCrossRef

89.

Efficace F, Bottomley A, Vanvoorden V, Blazeby JM. Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials. Eur J Cancer. 2004;40:187–97.PubMedCrossRef

90.

Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A. Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol. 2007;18:775–81.PubMedCrossRef

91.

Mauer ME, Taphoorn MJ, Bottomley A, Coens C, Efficace F, Sanson M, et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. J Clin Oncol. 2007;25:5731–7.PubMedCrossRef

92.

Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D'haese S, et al. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials—does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol. 2003;21:3502–11.PubMedCrossRef

93.

Sprangers MA, Moinpour CM, Moynihan TJ, Patrick DL, Revicki DA. Assessing meaningful change in quality of life over time: a users' guide for clinicians. Mayo Clin Proc. 2002;77:561–71.PubMedCrossRef

94.

Staquet M, Berzon R, Osoba D, Machin D. Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res. 1996;5:496–502.PubMedCrossRef

Titel: Health-related Quality of Life in Patients with Brain Tumors: Limitations and Additional Outcome Measures
verfasst von: Linda Dirven
Jacob C. Reijneveld
Neil K. Aaronson
Andrew Bottomley
Bernard M. J. Uitdehaag
Martin J. B. Taphoorn
Publikationsdatum: 01.07.2013
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 7/2013
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-013-0359-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2013

Epileptic Encephalopathy with Continuous Spikes and Waves During Sleep

Status Epilepticus: An Update

Novel Neuroimaging Modalities in the Evaluation of Spontaneous Cerebrospinal Fluid Leaks

Vesicular Integrity in Parkinson’s Disease

Congenital Abnormalities of the Optic Nerve: From Gene Mutation to Clinical Expression

Seizure-Related Injuries, Drowning and Vehicular Crashes – A Critical Review of the Literature